A medical assessment will confirm your multiple myeloma (MM) diagnosis according to international standards

Laboratory tests will measure your disease levels through blood and urine samples

The tests must show at least one of these results:

– Blood protein level of 0.5 g/dL or higher

– Urine protein level of 200 mg or more in 24 hours

– Special blood protein test showing levels of 10 mg/dL or higher

You will receive a combination of medications:

Daratumumab – given as an injection under the skin

Surzetoclax – taken by mouth as a film-coated tablet

Pomalidomide – taken by mouth

Dexamethasone – taken by mouth

Your health will be monitored through:

Regular blood tests

Physical examinations

Heart activity measurements (ECG)

Vital signs checks

Assessment of any side effects

Your response to treatment will be measured by:

Checking if the disease is getting better or worse

Measuring the amount of disease in your body

Monitoring how long the treatment keeps working

Testing for any remaining cancer cells

The study will continue until May 2029

Your overall health and survival will be monitored

Any need for additional treatments will be tracked

Regular assessments will continue throughout the study period